Abstract
Oncolytic virotherapy with mutants derived from Herpes simplex virus (HSV) type 1 exhibit significant antitumor effects in preclinical models. Several mutants have now been tested in clinical trials for a variety of cancer types, and all have been found to be safe. While there have been hints of antitumor efficacy with prolonged survival in some cases compared with historical controls, dramatic responses have been elusive. We review the clinical experience published to date and discuss some of the biologic factors that may be limiting for virus infection and spread, as well as new strategies currently under development to enhance antitumor efficacy.
Keywords: Herpes simplex virus, oncolytic viruses, tumor microenvironment, angiogenesis, extracellular matrix, cytokines, immune response
Current Pharmaceutical Biotechnology
Title:Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress
Volume: 13 Issue: 9
Author(s): Balveen Kaur, E. Antonio Chiocca and Timothy P. Cripe
Affiliation:
Keywords: Herpes simplex virus, oncolytic viruses, tumor microenvironment, angiogenesis, extracellular matrix, cytokines, immune response
Abstract: Oncolytic virotherapy with mutants derived from Herpes simplex virus (HSV) type 1 exhibit significant antitumor effects in preclinical models. Several mutants have now been tested in clinical trials for a variety of cancer types, and all have been found to be safe. While there have been hints of antitumor efficacy with prolonged survival in some cases compared with historical controls, dramatic responses have been elusive. We review the clinical experience published to date and discuss some of the biologic factors that may be limiting for virus infection and spread, as well as new strategies currently under development to enhance antitumor efficacy.
Export Options
About this article
Cite this article as:
Kaur Balveen, Antonio Chiocca E. and P. Cripe Timothy, Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress, Current Pharmaceutical Biotechnology 2012; 13 (9) . https://dx.doi.org/10.2174/138920112800958814
DOI https://dx.doi.org/10.2174/138920112800958814 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antioxidant Supplementation on Cancer Risk and During Cancer Therapy: An Update
Current Topics in Medicinal Chemistry The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design Human Immunodeficiency Virus-Induced Apoptosis of Human Breast Cancer Cells Via CXCR4 is Mediated by the Viral Envelope Protein But Does Not Require CD4
Current HIV Research Chemical and Clinical Development of Darinaparsin, a Novel Organic Arsenic Derivative
Anti-Cancer Agents in Medicinal Chemistry Withdrawal Notice: Electrophoresis as a Tool for Early Cancer Diagnosis
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem Cells Equipped with Powerful Hedgehog Signaling and Better Epigenetic Memory: Avenues to Look for Cancer Therapeutics
Current Cancer Drug Targets Targeted Tumor Immunotherapy: Are Vaccines the Future of Cancer Treatment?
Current Drug Therapy Cationic Liposomes as Non-viral Vector for RNA Delivery in Cancer Immunotherapy
Recent Patents on Drug Delivery & Formulation Gallic Acid Attenuates Oleic Acid-induced Proliferation of Vascular Smooth Muscle Cell Through Regulation of AMPK-eNOS-FAS Signaling
Current Medicinal Chemistry Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice
Current Drug Metabolism A Review on Theragnostic Applications of Micrornas and Long Non- Coding RNAs in Colorectal Cancer
Current Topics in Medicinal Chemistry Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Stem Cell Therapy: A Promising Approach in Treatment of COVID-19
Current Stem Cell Research & Therapy Design and Characterization of Mucoadhesive Gelatin-Ethylcellulose Microparticles for the Delivery of Curcumin to the Bladder
Current Drug Delivery Dicoumarol: A Drug which Hits at Least Two Very Different Targets in Vitamin K Metabolism
Current Drug Targets Kv7 Channels as Targets for the Treatment of Pain
Current Pharmaceutical Design Angiotensin Converting Enzyme-2: A Doorway for SARS-CoV-2
Coronaviruses Hydrogen Sulphide and Pain
Inflammation & Allergy - Drug Targets (Discontinued) Lymphoblastoid Cell Lines Models of Drug Response: Successes and Lessons from this Pharmacogenomic Model
Current Molecular Medicine